AGIOS PHARMACEUTICALS, INC.

AGIO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-314.7M $-198.5M $-117.7M $-53.5M $-39.4M $-20.1M $-23.7M
Depreciation & Amortization $6.4M
Depreciation $6.4M $5.7M $3.3M $1.4M $1.4M $1.2M $801.0K
Amortization
Stock-Based Compensation $47.8M $42.1M $32.0M $11.5M $3.0M $742.0K $371.0K
Net Cash from Operating Activities $-285.2M $38.6M $-76.9M $-59.4M $-56.4M $-49.5M $-15.2M
Investing Activities
Capital Expenditures $4.6M $9.9M $20.2M $2.2M $1.3M $1.5M $1.9M
Business Acquisitions
Net Cash from Investing Activities $-57.9M $-119.4M $128.3M $-87.2M $23.0M $-22.4M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $285.1M $169.8M $6.4M $123.9M $142.0K $77.4M
Net Change in Cash $-58.0M $89.0M $57.7M $-57.5M $-19.7M $-26.4M $39.8M
Free Cash Flow $-289.9M $28.6M $-97.1M $-61.6M $-57.7M $-51.0M $-17.1M
← Newer Page 2 of 2 Older →